Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention

Considering that prostate cancer lesions are not identifiable during surgery, except in the case of extensive and advanced tumors, the surgeon does not have a real-time perception of the location of the tumor. The absence of clear spatial visualization can therefore lead to a positive surgical margin, particularly in tumors in the T3 stage (invasion of the prostatic capsule or seminal vesicles).

Our hypothesis is that with the help of AI 3D AR during surgery, positive surgical margins can be avoided, or at least reduced, while preserving the neurovascular bundles, with a consequent improvement not only in postoperative functional outcomes (continence and potency), but also oncological ones (less biochemical disease recovery (BCR), less need for salvage radiotherapy, lower risk of metastasis).

Inclusion criteria

• Signature of the written informed consent and consent to the use of personal data
• Age > 40 years and male sex
• Pre-operative MRI performed according to ESUR recommendations and reporting in accordance with PiRads V.2
• Disease with evidence of bulging or radiological T3 on pre-operative MRI
• Histological diagnosis of acinar type prostate cancer in the area highlighted on MRI
• Absence of bulky (>3 cm), bony or visceral retroperitoneal or pelvic lymph node metastatic lesions
• Patients eligible for radical prostatectomy + pelvic lymphadenectomy
• ECOG PS 0-1
• Life expectancy ≥ 5 years
• Patients motivated to preserve erection and with pre-operative sexual activity with IIEF >17
• Availability of the patient's pre-operative clinical data
• Patients must be available to carry out the visits foreseen in the follow-up of the protocol and consent to data collection

Exclusion criteria

• Special histotypes of prostate cancer
• Patients with PSA > 100 ng/ml at diagnosis
• Inability to perform MRI (pacemaker wearers, claustrophobia...) or MRI of inadequate quality to obtain the HA3DTM 3D reconstruction
• Concomitant treatment with other antineoplastic drugs including investigational endocrine therapies
• Serious uncontrolled concomitant medical condition or disease including active, uncontrolled infections
• Patients with dementia or psychiatric illness that limit compliance with study requirements or that may prevent understanding and/or signing informed consent.